Opinion|Videos|July 8, 2024
EMERALD Study Design and Results for Elacestrant
Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.
Advertisement
Episodes in this series
- Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (
Shah et al. J Clin Oncol. 2024 )- How have the EMERALD trial impacted your use of Elacestrant in clinical practice, particularly in terms of patients’ selection and treatment sequencing?
- What are your impressions of the overall and subgroup data from EMERALD? Does it expand the ideal patient population for elacestrant?
- For a patient with metastatic breast cancer to bones, liver, and lungs who has an ESR1 mutation, how does this inform treatment selection between continuing endocrine therapy versus switching to other targeted agents or chemotherapy?
- Would elacestrant be an ideal next line treatment for this patient?
Advertisement
Related to this article
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5